MicroProtein Technologies Inc., was founded by Vinod Pandiripally Ph.D. with the purpose of commercializing novel and cutting-edge methods for the culture of E. coli to produce recombinant biologics (proteins and plasmid DNA)
After years of proprietary research and development, MicroProtein Technologies Inc. has developed a robust solid media-based E. coli manufacturing platform, MPTxpress, which far surpasses conventional fermentation as a reliable and inexpensive way to produce recombinant proteins.
MPTxpress has advantages including higher yields with incredible simplicity and related cost savings, including no need for bioreactors, mixers, etc.; is fully singleuse; minimizes up-stream and down-stream processing; and eliminates the need for expensive fixed stainless steel equipment. E. coli is cultured on top of a membrane laid on top of 12-inch square agar plates, with harvesting involving scraping concentrated protein paste off the membrane. Each plate produces >1 gram of protein after incubation overnight at room temperature in a standard lab incubator. MPTxpress is scalable to commercial manufacture, e.g., ≥1 kg/day – simply use more trays (mini bioreactors in parallel)
Read more about our novel upstream and fermentation process in our feature in BioProcess International here and in Genetic Engineering Biotechnology News here.
MicroProtein Technologies Inc. (MPT) is a pioneer in the field of biotechnology, offering microbial and E.coli CDMO, CMO, CRO services using MPTxpress, a unique solid-state/liquids- and stress-free E. coli manufacturing platform; and commercializing other antibody affinity proteins and resins with greatly improved pH tolerance and than competing resins. Using our patented MPTxpress technology, we aim to lead the industry in the production of microbially-expressed recombinant proteins, enzymes, cytokines, antibodies and anti body fragments, growth factors and plasmid DNA for use in biopharmaceuticals, diagnostics, reagents, veterinary medicine, non-clinical academic and industrial applications. Read more…
Formulation: Lyophilized Salt-free powder
Product#: MPT-SA-100
Formulation: Lyophilized Salt-free powder
Product#: hIL-2L0.5mg
Formulation: Lyophilized Salt-free powder
Product#: A100L20
Formulation: Lyophilized Salt-free powder
Product#: G100L20
Formulation: Lyophilized Salt-free powder
Product#: AG100L10
Formulation: Lyophilized Salt-free powder
Product#: L100L10
During the research and development of protein-based therapeutics, finding the optimal conditions for protein production is often a time-consuming and labor intensive process.
The R&D pipeline for new drugs has changed considerably over the past decade. Once dominated by big pharma and small molecules, today’s pipeline is increasingly populated with small and emerging biotech companies developing large molecules, or biologics, which now make up nearly 40% of the active R&D pipeline globally.
Fibroblast Growth Factor-Basic (FGFb) is a critical component for maintaining stem cells in culture in an undifferentiated state.
Streptavidin is a biotin-binding protein found in culture broth of the bacterium Streptomyces avidin. Streptavidin binds 4 moles of biotin per mole of protein with a remarkably high affinity.
Interleukin-2 (IL-2) is one of a family of polypeptides that mediate interactions between leukocytes. It is a T-cell growth factor.
Proprietary recombinant Protein A
is produced using our proprietary
MPTxpress solid-state E. coli expression system. This Protein A functions essentially the same as native Protein A.
The gene we selected to use for the production of Protein G originated from Streptococcus Strain G148, and was cloned and expressed in our proprietary strain of Escherichia coli.
Our recombinant Protein A/G is a fusion protein that comprises of a total of 7 IgG-binding domains EDABC-C2C3. This fusion protein combines the active Fc-binding domains of Protein A and Protein G that are contained in the recombinant sequence.
Recombinant Protein L is expressed by MicroProtein Technologies in E.coli using its MPTxpress upstream platform with innovative purification methods.
Recombinant Biologics Manufacturer CDMO – CMO
Copyright © 2024. All rights reserved.